IRIS UniCatt

Andreotti, Felicita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.016
EU - Europa 2.559
AS - Asia 1.495
SA - Sud America 192
AF - Africa 30
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 7.311
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.989
SE - Svezia 664
SG - Singapore 604
DE - Germania 569
CN - Cina 557
IT - Italia 343
IE - Irlanda 212
UA - Ucraina 210
BR - Brasile 175
FR - Francia 139
ID - Indonesia 132
GB - Regno Unito 113
RU - Federazione Russa 99
FI - Finlandia 63
IN - India 42
TR - Turchia 38
HK - Hong Kong 29
NL - Olanda 25
BE - Belgio 22
AT - Austria 17
CA - Canada 12
KR - Corea 12
CZ - Repubblica Ceca 11
IR - Iran 11
AU - Australia 10
CH - Svizzera 10
JP - Giappone 10
ET - Etiopia 9
EU - Europa 8
PL - Polonia 8
IQ - Iraq 7
MX - Messico 7
ZA - Sudafrica 7
BD - Bangladesh 6
RO - Romania 6
VN - Vietnam 6
BG - Bulgaria 5
ES - Italia 5
LT - Lituania 5
CI - Costa d'Avorio 4
DO - Repubblica Dominicana 4
EC - Ecuador 4
LU - Lussemburgo 4
MA - Marocco 4
PK - Pakistan 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CO - Colombia 3
DK - Danimarca 3
HU - Ungheria 3
IL - Israele 3
KW - Kuwait 3
LV - Lettonia 3
PE - Perù 3
PT - Portogallo 3
QA - Qatar 3
SA - Arabia Saudita 3
AL - Albania 2
AR - Argentina 2
BT - Bhutan 2
BY - Bielorussia 2
CY - Cipro 2
GR - Grecia 2
IS - Islanda 2
KE - Kenya 2
KG - Kirghizistan 2
LK - Sri Lanka 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
UZ - Uzbekistan 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BZ - Belize 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
HN - Honduras 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MC - Monaco 1
ME - Montenegro 1
MK - Macedonia 1
MU - Mauritius 1
NO - Norvegia 1
OM - Oman 1
SI - Slovenia 1
TN - Tunisia 1
UG - Uganda 1
Totale 7.311
Salva come PNG Salva come JPEG
Città #
Chandler 607
Singapore 351
Ashburn 348
Dublin 205
San Mateo 159
Jakarta 131
Hangzhou 116
Wilmington 112
Jacksonville 105
Beijing 100
Nanjing 99
New York 94
Cattolica 93
Boston 86
Princeton 83
Moscow 73
Milan 66
Ann Arbor 54
Menlo Park 52
Lancaster 50
Bremen 49
Rome 46
Redwood City 38
Los Angeles 37
Dearborn 35
Woodbridge 35
Fairfield 34
Nanchang 34
Marseille 33
Munich 32
Seattle 30
Lawrence 29
Houston 27
Izmir 27
Hong Kong 25
Chicago 24
Boardman 21
Frankfurt am Main 21
Brussels 20
Mountain View 18
Nuremberg 18
Nürnberg 18
Norwalk 17
Redmond 17
Shenyang 15
São Paulo 15
Helsinki 14
Pune 14
Düsseldorf 13
Shanghai 13
Zhengzhou 13
Hebei 12
Kunming 12
Jiaxing 11
Padova 11
Vienna 11
Washington 11
Augusta 10
Falkenstein 10
Groningen 10
Leawood 10
Tianjin 10
Busto Arsizio 9
Changsha 9
Hyderabad 9
London 9
Andover 8
Detroit 8
Guangzhou 8
Toronto 8
University Park 8
Florence 7
Paris 7
Zhongxin 7
Cambridge 6
Gunzenhausen 6
Hanoi 6
Zurich 6
Cuautitlán Izcalli 5
Istanbul 5
Lappeenranta 5
North Bergen 5
Santa Clara 5
Sofia 5
The Dalles 5
Abidjan 4
Belo Horizonte 4
Dallas 4
Hefei 4
Juiz de Fora 4
Kish 4
Luxembourg 4
Madrid 4
Portsmouth 4
Rio de Janeiro 4
San Diego 4
Santa Maria 4
Santo Domingo 4
Seoul 4
Suwon 4
Totale 4.100
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 165
Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women 160
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 148
Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients 127
Intraventricular conduction abnormalities in young patients with type 1 diabetes mellitus 126
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function 126
Impact of coronary stenting on top of medical therapy and of inclusion of periprocedural infarctions on hard composite endpoints in patients with chronic coronary syndromes: a meta-analysis of randomized controlled trials 114
Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction 103
Bedside monitoring of antiplatelet therapy for coronary stenting 102
Body fat and cardiovascular risk: understanding the obesity paradox 99
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 98
IGF-1 and microvascular complications of diabetes: alternative interpretation of recently published data 93
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials 88
Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS) 87
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 87
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 86
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome 85
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 85
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology 84
Testosterone, tissue factor inhibition and vascular aging 83
Anemia contributes to cardiovascular disease through reductions in nitric oxide 83
A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. 82
Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of STEMI 80
Hemoglobin levels, nitric oxide bioavailability and cardiovascular outcomes 77
Last word on viewpoint: Anemia contributes to cardiovascular disease through reductions in nitric oxide 77
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 77
Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology 76
Sex differences in mechanisms, presentation and management of ischaemic heart disease 76
Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies 73
EuroThrombosis: annual meeting of the European Society of Cardiology Working Group on Thrombosis 72
Mechanisms, pathophysiology, and management of obesity 72
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 72
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor 68
Polycythemia, vascular function, and hemoglobin-nitric oxide reactions 67
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis 67
[Inflammatory and fibrinolytic activation after coronary artery bypass with extracorporeal circulation] 66
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 66
Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials 65
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis 65
The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? 65
Evolocumab and clinical outcomes in patients with cardiovascular disease 65
Bedside monitoring of antiplatelet therapy for coronary stenting 63
Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization 63
Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: A systematic review and meta-analysis 63
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 63
Leading avoidable cause of premature deaths worldwide: case for obesity 61
Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass 61
Women and coronary disease 59
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis 59
4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: A prospective study 59
Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials 58
Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism 58
Mechanisms, Pathophysiology, and Management of Obesity 58
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: A jump with a weak parachute? 58
Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients 58
The unstable plaque: a broken balance 57
Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery 57
Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial) 57
Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes 57
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper 56
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population 55
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS 55
Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis 55
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis 55
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 54
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: A review 54
Family history in first degree relatives of patients with premature cardiovascular disease 54
Sex- and gender‑specific precision medicine for chronic coronary syndromes: challenges and opportunities 54
Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: Not a matter of faith 54
Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives 53
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 53
Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine 53
Stakeholders in NOACs prescription: Authors' reply 52
The G20210A prothrombin mutation and the Physicians' Health Study 52
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management 51
G20210A prothrombin gene polymorphism and extent of coronary disease 51
Role of PAPP-A in atherothrombosis: messages to take home 50
Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry 50
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 50
Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes 49
Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention? 49
Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials 48
Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure 48
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 47
Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes 47
Reversible left anterior descending artery spasm, prolonged cardiac arrest and left main thrombosis during a PTCA attempt of the circumflex artery 46
Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions 46
Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation 45
Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: A systematic review and meta-analysis 45
Defining the role of left atrial appendage closure in atrial fibrillation 43
Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease 43
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: The 'OPTIMIZE-IT' pilot randomized study 43
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial 42
Glycoprotein la C807T qene polymorphism and increased risk of recurrent acute coronary syndromes: A five year follow up 40
Fibrinogen as a marker of inflammation: a clinical view 38
Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering a systematic review and meta-analysis 38
Methodological education in response to the quality of COVID-19 publications 36
Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal 35
Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis 34
Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel 34
Totale 6.683
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.182
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020159 0 0 0 0 0 0 0 0 0 0 77 82
2020/2021524 63 52 7 42 60 32 58 8 66 20 110 6
2021/2022922 73 63 8 66 54 23 20 165 39 50 192 169
2022/20231.946 306 254 148 249 141 230 78 153 247 41 67 32
2023/20241.164 45 291 23 154 29 139 59 105 25 41 133 120
2024/20251.317 44 52 148 78 163 54 50 128 398 174 28 0
Totale 7.466